NeoGenomics Pharma Services uses NanoString nCounter® technology in providing translational research services to our clients. NanoString nCounter® is able to multiplex up to 800 targets in a single reaction with no amplification and counts targets digitally, delivering superior performance and reproducibility. This flexible platform can help translate oncology signatures from research to clinic. Services are performed under the NeoGenomics quality management system for use in research, discovery, and clinical trials, as applicable. Validation services are available.
Benefits of using NanoString nCounter
Cost-effective compared to similar technologies
Quantitative assessment of bulk gene expression changes
Rapid turnaround time
User-friendly data analysis
Examples of NanoString nCounter Panels and Assays offered by NeoGenomics:
PanCancer Immune profiling panel (analytically validated)
Human PanCancer IO360 Panel (analytically validated)
PanCancer Pathways Panel
Metabolic Pathways Panel
Prosigna (validated and on clinical test menu)
Lymphoma Subtyping Test (LST)/COO panel
CAR-T Characterization Panel
miRNA Expression Panel
Custom Panels Available
NeoGenomics also offers custom panels such as CodeSet Plus, Panel Plus, Elements TagSets, PlexSet and Vantage 3D assays. Pair the panels with Data Analysis Service to receive 48 signature scores including TIS, PAM50, or more.
GeoMx™ Digital Spatial Profiler (DSP)
NeoGenomics Pharma Services also uses NanoString GeoMx Digital Spatial Profiler (DSP) in providing spatial omics services to our clients. GeoMx DSP combines standard immunofluorescence techniques with digital optical barcoding technology to perform morphologically guided, highly multiplexed, spatially resolved tissue profiling. Being a non-destructive method, it also allows the same tissue to be profiled with different sets of antibody cocktails. In combination with NanoString nCounter or NGS readout, GeoMx DSP enables spatially resolved high-plex profiling of RNA and protein targets enabling a deep characterization of the tissue sample.
GeoMx RNA Panels Offered by NeoGenomics
GeoMx RNA assays include the RNA Immune Pathways Panel, Cancer Transcriptome Atlas, and Whole Transcriptome Atlas that allow gene expression analysis with spatial resolution from distinct regions of interest from a single FFPE or fresh frozen slide using DSP.
GeoMx RNA assays|
RNA Immune Pathways Panel|
The curated content in the RNA Immune Pathways Panel is designed for immuno-oncology research and is customizable with up to 10 additional targets of interest. Tumor Inflammation Signature (TIS) is also included.|
Cancer Transcriptome Atlas|
Cancer Transcriptome Atlas profiles expression of >1,800 genes for a detailed look at the global immune response. The assay quantifies tumor reactivity to the immune response and therapeutic treatments, and includes TIS & the 50-gene Prediction Analysis of Microarray 50 signature (PAM50).|
Whole Transcriptome Atlas|
Whole Transcriptome Atlas is designed for discovery research and provides an unbiased view of 18,000+ protein-coding genes and can explore any target and pathway in biological regions of interest. The assay is also customizable with the ability to add spike in genes of interest.|
GeoMx Protein Assays offered by NeoGenomics
GeoMx Protein Assays enable quantitative, spatial analysis of a wide range of protein targets from a single FFPE or Fresh Frozen slide. NeoGenomics offers a family of GeoMx Protein Assays with a focus on cancer and immunology.
GeoMx Protein Assays|
Immune Cell Profiling Core|
The Immune Cell Profiling Core includes key immuno-oncology targets and markers of immune cell types, including T cells, B cells, macrophages, NK cells, epithelia, and stroma with necessary controls.|
Immune Cell Typing Module|
This module includes an expanded set of cell type markers to more deeply profile immune cell types covered in the Immune Cell Profiling Core and measure additional immune cell types, including T cell subsets.|
Immune Activation Status Module|
This module includes additional checkpoint molecules that modulate T cell activation.|
IO Drug Target Module|
This module includes drug targets in development within the immuno-oncology space, including checkpoint molecules and metabolic mediators of immune function.|
This module includes an expanded set of markers for detecting specific tumor types, including ER+/HER2+ breast tumors, hematopoietic malignancies, and melanoma.|
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients